NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary Chapter: 5 - Infections 
Notes:

For full details on UKHSA guidance for managing common infections with local amendments please see:

BLMK Primary Care Antimicrobial Guidelines hosted via: https://blmkantibioticspubliclive.azurewebsites.net/

Secondary care antimicrobial guidelines:

Bedfordshire Hospitals Foundation Trust: Antimicrobial guidelines are hosted on:  EOLAS Medical App. 
05.03 Antiviral drugs

Baricitinib (Olumiant® ( 2mg and 4 mg tablets))

RED
Restricted Drug Restricted

For use in line with NHSE Interim commissioning policy

 

Entry reviewed: November 2022

BNF BNFc SPC
MHRA DSU April 2023 - Janus kinase (JAK) inhibitors: new measures to reduce risks of major cardiovascular events, malignancy, venous thromboembolism, serious infections and increased mortality

Molnupiravir capsules (Lagevrio®)

RED
Restricted Drug Restricted

FOR ALL TRUST PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

To be prescribed by specialists in the Covid Medicines Delivery Unit (CMDU) or secondary care in accordance with NICE TA recommendations only:

 

Entry reviewed: May 2025

BNF BNFc SPC
NICE TA1056: Molnupiravir for treating COVID-19

Nirmatrelvir 150mg with ritonavir 100mg tablets (Paxlovid®)
(150 mg/100 mg film-coated tablets)

RED
Restricted Drug Restricted

FOR ALL TRUST PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

To be prescribed by specialists in the Covid Medicines Delivery Unit (CMDU) or secondary care in accordance with NICE TA recommendations only: 

 

Entry reviewed: June 2025

BNF BNFc SPC
Medicine Request Form - Nirmatrelvir/Ritonavir (Paxlovid) MHRA DSU Nov 2023 Nirmatrelvir, ritonavir (Paxlovid▼): be alert to the risk of drug interactions with ritonavir NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

Remdesivir 100mg (Veklury®)
(Powder for concentrate for solution for infusion)

RED
Restricted Drug Restricted

Approved in accordance with the NICE TA below.

Patients must fulfil set criteria to be eligible for this medicine - contact Pharmacy for information if needed.

N.B.  We will not receive any further supplies unless the required paperwork is completed. Paperwork needed:

Medicine Request form at initiation; ISARIC clinical outcome form; adverse event form.

Contact your ward pharmacist or pharmacy for supply.

L&D - Out of hours some stock is available in the emergency cupboard fridge. Contact 555 to access or on-call pharmacist for information.

Bedford - Out of hours contact the oncall Pharmacist

BNF BNFc SPC BlueTeq
NICE TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 Remdesivir - Interim Procedure for Prescribing and Access Medicine Request Form (Bedford) - Remdesivir Medicine Request Form (Luton) - Remdesivir Adverse event form

Sotrovimab Infusion (Xevudy®)
(500 mg concentrate for solution for infusion)

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

For use in line with NICE TA recommendations only.

 

Due to be discontinued 27 February 2026.

 

Entry reviewed: Dec 2025

BNF BNFc SPC
Medicine Request Form - Sotrovimab NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

Tocilizumab (Tyenne ®)
(COVID-19 )

RED
Restricted Drug Restricted

FOR ALL PRESCRIBING – Blueteq or High cost drug form required – see link from Formulary homepage.

To be used in accordance with NICE TA recommendations only.

Preferred brand: Tyenne®

Originator brand: RoActemra®

Entry reviewed: May 2024

BNF BNFc SPC
Medicine Request Form - Tocilizumab NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 Tocilizumab Prescription and Administration Form
Classifications
GREEN
May be initiated in any care setting
Amber SPA
Specialist to advise therapy and provide first 28 days supply, continuation in Primary Care
Amber SPIS
Specialist to initiate and stabilise medicine prior to continuation in Primary Care
SCG
To be prescribed as per Shared Care Guidance. If no SCG in place status reverts to red.
RED
Red medicines are designated as specialist only medicines which should only be prescribed by a specialist, usually within secondary care (either due to the requirement for specialist knowledge, long-term monitoring requirements, or restrictions that mean medicine supplies are only available to hospitals).
DNP
A decision has been made either locally and/or nationally not to routinely commission this preparation. Do not prescribe.
SELF
To be purchased over the counter. May be prescribed for chronic, long term conditions or on admission to hospital if essential.